MET and cancer: Additionally, another potential therapeutic target for preventing the induction of EMT is hepatocyte growth factor (HGF)-HGR receptor (HGFR, MET) signaling, which contributes to cancer pathogenesis, as exemplified by its frequent activation, often by point mutation or amplification of the MET, in many cancer types [131].